<DOC>
	<DOCNO>NCT01618253</DOCNO>
	<brief_summary>To determine maximum tolerated radiation dose concurrent sorafenib unresectable hepatocellular carcinoma respond transarterial chemoembolization .</brief_summary>
	<brief_title>Radiation Therapy With Sorafenib TACE-Resistant Hepatocellular Carcinoma</brief_title>
	<detailed_description>In patient unresectable hepatocellular carcinoma ( HCC ) , transarterial chemoembolization ( TACE ) first line therapy . Non-responders TACE ( i.e . stable progressive disease ) represent poor prognosis population limit option . Sorafenib indicate first line salvage therapy , however improve survival 2-3 month 2-3 % response rate . Thus , sorafenib merely cytostatic agent delay progression cytoreduce disease . Radiation therapy ( RT ) non-invasive treatment cytoreduce HCC minimal morbidity use modern technique . A meta-analysis multiple retrospective series suggest TACE + RT improve survival compare TACE alone . Higher RT dose similarly associate increased survival due improve local control . Paradoxically , series suggest RT induce vascular endothelial growth factor ( VEGF ) expression may stimulate HCC . Pre-clinical data suggest combine RT concurrent sorafenib ( VEGF inhibitor ) improve tumor control . However , clinical data limit case report safety well characterize . Prior determine combination improve control HCC poor prognosis population , optimal radiation dose concurrent sorafenib must determine phase I dose escalation trial .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Radiographic histologic diagnosis hepatocellular carcinoma ( HCC ) . Maximum 3 HCC lesion within liver . No evidence lymphadenopathy metastatic disease per either CT PET . Prior transarterial chemoembolization ( TACE ) least 28 day prior initiation protocol therapy . Evidence either progressive disease stable disease follow TACE . Child Pugh Class A ( score 56 ) B ( score 7 ) . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤1 ( Karnofsky ≥70 % ) . Normal organ marrow function ( platelet &gt; 60,000/mc ; hemoglobin ≥8.5 g/dL ; international normalize ratio ( INR ) ≤2.3 ; albumin ≥2.8 g/dL ; total bilirubin ≤3 mg/dL ; aspartate aminotransferase ( AST ) / alanine aminotransferase ( ALT ) &lt; 5x upper limit normal ; creatinine ≤1.5x upper limit normal ) . Negative human immunodeficiency virus serology . Negative pregnancy test woman child bear age . Ability understand willingness sign write informed consent document . Less 800 cc normal liver . Child Pugh Class B ( score 89 ) C ( score 1015 ) . Acute/active hepatitis B infection . Prior systemic chemotherapy abdominal radiation therapy . Portal venous ( main , primary right , primary leave trunk ) inferior vena cava thrombosis . Prior malignancy within 5 year enrollment except nonmelanoma skin cancer . Prior history myocardial infarction , cerebrovascular accident , esophageal variceal bleed last 6 month . Preexisting heart failure either clinical classification New York Heart Association Class III IV cardiac ejection fraction &lt; 45 % . Systolic blood pressure &gt; 160 mmHg diastolic pressure &gt; 100 mmHg despite optimal medical management . Pulmonary hemorrhage serious bleed event ( grade 2+ ) within 4 week initiation protocol therapy . Prior history scleroderma active systemic lupus erythematosus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Transarterial Chemoembolization</keyword>
	<keyword>TACE</keyword>
	<keyword>Sorafenib Tosylate</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Nexavar</keyword>
	<keyword>External Beam Radiation Therapy</keyword>
	<keyword>Radiation Therapy</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Radiation</keyword>
</DOC>